Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD5044 in Chinese Participants With Hypertriglyceridemia
NCT07587788Phase 2Active, not recruiting
- Sponsor
- Ribotek
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rbd5044 in hypertriglyceridemia (3 arms), sponsored by Ribotek. Primary endpoint: Fasting serum triglyceride levels at Week 16. Started Feb 2026; status: active, not recruiting.
02
Drugs
rbd5044
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT07587788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587788.